Get started
KUROS BIOSCI.AG NAM.SF-,1KUROS BIOSCI.AG NAM.SF-,1KUROS BIOSCI.AG NAM.SF-,1

KUROS BIOSCI.AG NAM.SF-,1

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

YTSN chart


Full chart

YTSN upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.06 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.12 EUR
Net income (FY)
‪−4.56 M‬ EUR
Revenue (FY)
‪80.36 M‬ EUR
Shares float
‪25.97 M‬
Beta (1Y)
1.26

Employees


Employees (FY)
4
Change (1Y)
−1 −20.00%
Revenue / Employee (1Y)
‪20.09 M‬ EUR
Net income / Employee (1Y)
‪−988.10 K‬ EUR

About KUROS N


Sector
Health Technology
Industry
Biotechnology
CEO
Christopher T. Fair
Website
kurosbio.com
Headquarters
Schlieren
Founded
2000
ISIN
CH0325814116
FIGI
BBG000FG63V0
Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

YTSN news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as YTSN.

Frequently Asked Questions


The current price of YTSN is 26.94 EUR — it has increased by 0.50% in the past 24 hours. Watch KUROS BIOSCI.AG NAM.SF-,1 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange KUROS BIOSCI.AG NAM.SF-,1 stocks are traded under the ticker YTSN.
YTSN stock has risen by 10.44% compared to the previous week, the month change is a 14.17% rise, over the last year KUROS BIOSCI.AG NAM.SF-,1 has showed a ‪1.53 K‬% increase.
We've gathered analysts' opinions on KUROS BIOSCI.AG NAM.SF-,1 future price: according to them, YTSN price has a max estimate of 28.92 EUR and a min estimate of 28.92 EUR. Watch YTSN chart and read a more detailed KUROS BIOSCI.AG NAM.SF-,1 stock forecast: see what analysts think of KUROS BIOSCI.AG NAM.SF-,1 and suggest that you do with its stocks.
YTSN reached its all-time high on May 5, 2025 with the price of 31.16 EUR, and its all-time low was 1.28 EUR and was reached on Jan 25, 2019. View more price dynamics on YTSN chart.
See other stocks reaching their highest and lowest prices.
YTSN stock is 5.27% volatile and has beta coefficient of 1.26. Track KUROS BIOSCI.AG NAM.SF-,1 stock price on the chart and check out the list of the most volatile stocks — is KUROS BIOSCI.AG NAM.SF-,1 there?
Today KUROS BIOSCI.AG NAM.SF-,1 has the market capitalization of ‪1.11 B‬, it has increased by 4.49% over the last week.
Yes, you can track KUROS BIOSCI.AG NAM.SF-,1 financials in yearly and quarterly reports right on TradingView.
KUROS BIOSCI.AG NAM.SF-,1 is going to release the next earnings report on Aug 13, 2025. Keep track of upcoming events with our Earnings Calendar.
KUROS BIOSCI.AG NAM.SF-,1 revenue for the last half-year amounts to ‪46.48 M‬ EUR, despite the estimated figure of ‪48.18 M‬ EUR. In the next half-year revenue is expected to reach ‪57.17 M‬ EUR.
YTSN net income for the last half-year is ‪−4.34 M‬ EUR, while the previous report showed ‪−219.11 K‬ EUR of net income which accounts for ‪−1.88 K‬% change. Track more KUROS BIOSCI.AG NAM.SF-,1 financial stats to get the full picture.
No, YTSN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 14, 2025, the company has 4 employees. See our rating of the largest employees — is KUROS BIOSCI.AG NAM.SF-,1 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KUROS BIOSCI.AG NAM.SF-,1 EBITDA is ‪2.73 M‬ EUR, and current EBITDA margin is 3.40%. See more stats in KUROS BIOSCI.AG NAM.SF-,1 financial statements.
Like other stocks, YTSN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KUROS BIOSCI.AG NAM.SF-,1 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KUROS BIOSCI.AG NAM.SF-,1 technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KUROS BIOSCI.AG NAM.SF-,1 stock shows the buy signal. See more of KUROS BIOSCI.AG NAM.SF-,1 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.